Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eryaspase plus gemcitabine and carboplatin versus chemotherapy alone in recurrent or metastatic triple-negative breast cancer
2018-002211-10Phase 2Unknown
- Sponsor
- PHAXIAM Therapeutics
- Start
- Aug 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of eryaspase in triple-negative breast cancer (TNBC) (2 arms), sponsored by PHAXIAM Therapeutics. Primary endpoint: Disease control rate. Status: unknown.
02
Drugs
eryaspase
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2018-002211-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002211-10.